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Michael Fayon9, Véronique Houdouin10,11, Michèle Berlioz-Baudoin1, Virginie Feret9, Thierry Leblanc12,
Karine Morelle7, Marc Albertini1,2, Annick Clement5,6, Jacques de Blic3,4 and for the French Respirare® Group
Abstract
Background: Idiopathic eosinophilic pneumonia is extremely rare in children and adults. We present herein the first
series describing the specificities of idiopathic chronic (ICEP) and acute (IAEP) eosinophilic pneumonia in children.
Methods: We retrospectively analyzed all cases of ICEP and IAEP in children that were retrieved from French Reference
Centers for rare pediatric lung diseases.
Results: Five cases of pediatric ICEP were identified. Corticosteroid or immunosuppressive therapy dramatically
improved the outcome in three cases. The remaining two cases had a persistent interstitial pattern with progressive
development of cystic airspace lesions. Three cases of IAEP in adolescents were reported, with one requiring four days
of extracorporeal membrane oxygenation.
Conclusion: ICEP is a rare disease with a polymorphic clinical presentation in children. We identified patients with
persistent interstitial patterns progressing to cystic airspace regions, for which the boundaries with idiopathic interstitial
pneumonias are difficult to establish. We therefore propose a specific pediatric definition and classification algorithm.
IAEP in children remains an inflammatory reaction of the lung to an acute toxic exposure, mainly tobacco, as in adults.
International studies are required to comprehensively assess the various clinical forms of the disease as well as the
appropriate therapeutic regimens.
Keywords: Idiopathic chronic eosinophilic pneumonia, Idiopathic acute eosinophilic pneumonia, Child, Eosinophilic
lung disease, Interstitial lung disease
Introduction
Eosinophilic pneumonias (EP) [1] are diffuse, parenchymal
lung diseases (DPLD) characterized by prominent eosino-
phil infiltration in the pulmonary interstitium and alveolar
airspaces, exerting a major role in tissue injury. EP are di-
vided into two groups: (i) secondary forms (seen mainly in
parasitic infections, allergic bronchopulmonary aspergil-
losis (ABPA) and drug reactions, but also in other infec-
tions and neoplasia) and (ii) idiopathic forms (Eosinophilic
Granulomatosis with Polyangiitis, idiopathic hypereosino-
philic syndrome, idiopathic chronic eosinophilic pneumo-
nia (ICEP) and idiopathic acute eosinophilic pneumonia
(IAEP)). Idiopathic eosinophilic pneumonias are rare en-
tities and pediatric case descriptions are scarce. They most
likely do not represent one single, clearly defined disease
entity but, rather, a common phenotype which shares pro-
nounced eosinophilia but does not fulfill strict definitions
or criteria. To date, no series of pediatric ICEP or IAEP
have been reported. The objective of this multicenter
retrospective study was to analyze cases of ICEP and IAEP
in children.
Patients and methods
Recruitment
Three cases of ICEP were identified from the national,
internet-linked database (created in 2008) for pediatric
interstitial lung disease (ILD) of the National Reference
Center for Rare Lung Diseases (Respirare®, http://www.
respirare.fr) [2]. Data were available for 217 cases of ILD,
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with “eosinophilic lung diseases” being one of the less-
frequent etiologies (5/217) [2].
As acute diseases are not included in the registry, cases of
IAEP were retrieved by mailing to all members of the Na-
tional Reference Center and to all members of the “Groupe
Francophone de Réanimation et d’Urgences Pédiatriques”.
This mailing process also permitted the identification of
two supplementary cases of ICEP not yet registered and
four other cases of eosinophilic lung diseases.
Data collection
A detailed questionnaire regarding the initial presenta-
tion, investigations, elimination of differential diagnoses,
treatment, outcome and follow-up was sent to referring
physicians.
Inclusion criteria for ICEP and IAEP [3] were based
on adult series (Table 1).
Six cases of EP were excluded because of the following:
hypereosinophilic asthma (two cases); Eosinophilic Granu-
lomatosis with Polyangiitis diagnosis (three cases); positive
serologic test for Wuchereria bancrofti (one case).
Statistical analysis
Due to the small number of patients in each group and
the non normal distribution of values, we have presented
median values with interquartile ranges.
Results
ICEP
Epidemiological data and medical history
Five patients were identified (Table 2). There were four
girls and one boy (sex ratio: 0.25). Mean age at diagnosis
was 11.17 [6.83-13.92] years. All patients lived in metro-
politan France at the time of diagnosis except for case 3
who lived in Martinique (a tropical overseas French terri-
tory in the Caribbean). Case 4 was born in Mali and case 1
had previously lived in Mayotte (another tropical overseas
French territory in the Mozambique Channel). Three pa-
tients had a history of atopy, with three having asthma,
two allergic rhinoconjunctivitis, two atopic dermatitis (one
with a severe form), and one multiple food allergy (sea-
food, peanut, egg).
Clinical data
The median period between the onset of respiratory
symptoms and diagnosis was 60 [60-90] days. Cough was
the initial symptom in all cases (mostly dry cough: 4/5).
Systemic symptoms always appeared secondarily, with a
median period of 30 [25.5-30] days. Fever was present in
only one patient (1/5) (case 1).
Radiological data
Chest X-rays were abnormal in four patients, with two
having dense infiltrates of the right upper lobe and two
having bilateral, ill-defined, hazy increased densities. A
high-resolution computed tomograph (HRCT) chest scan
showed a typical adult-type ICEP presentation, including bi-
lateral peripheral ground-glass and consolidation opacities
(present in, respectively, 88 and 100% of adults with ICEP
in a series of 80 readings) [4] in only two patients (cases 1
and 2) (Figure 1a). The three others presented only with
interstitial opacities which were diffuse in cases 3 and 5 and
patchy in the inferior lobes in case 4 (Figure 1a and 2a).
Biological data
The blood eosinophil count on admission was > 1,000/mm3
in four patients, with a median of 1,510 [1,100-4,601]. IgE
levels were elevated in all patients, with a median of
799 [165-1,040] kU/L. Cases 1 and 3 had antinuclear
antibodies. Immunophenotypic studies identified an
abnormal T-cell clone in case 4. Clonal TCR-γ rearrange-
ment was identified in case 5 but without aberrant cell
surface immunophenotype.
Bronchoalveolar lavage fluid analysis
Median BALF cellularity was 240,000 [160,000-390,000]/
mm3. BALF eosinophilia was present in all cases, with a
median of 28 [20-44] %.
Table 1 ICEP and IAEP inclusion criteria based on adults series3
Inclusion criteria for ICEP based on adults series3 Inclusion criteria for IAEP based on adults series3
1) respiratory symptoms present> 2 weeks 1) acute onset with febrile respiratory symptoms (< 1 month, and especially
< 7 days duration before medical examination)
2) diffuse pulmonary alveolar consolidation with air bronchogram
and/or ground-glass opacities at chest imaging, especially with
peripheral predominance
2) bilateral diffuse infiltrates on imaging
3) eosinophil count in bronchoalveolar lavage fluid (BALF) > 40%
and/or peripheral blood eosinophilia > 1x109cells/L
3) PaO2 in room air < 60 mmHg, or PaO2/FiO2 < 300 mmHg, or oxygen
saturation (SpO2) in room air < 90%
4) absence of other known causes of eosinopilic lung disease* 4) lung eosinophilia with > 25% eosinophils in BALF
5) absence of determined cause of acute eosinophilic pneumonia*
(including infection or drug exposure) - recent onset of tobacco smoking
or exposure to inhaled dusts may be present
Footnote: * We excluded patients with evidence of: 1) exposure to drugs inducing pulmonary eosinophilia, according to the Pneumotox website (http://www.
pneumotox.com); 2) ABPA; 3) positive stool parasite test or positive serologic test for Toxocara canis, Trichinella spiralis, Fasciola hepatica, Strongyloides stercoralis,
Brugia malayi or Wuchereria bancrofti; 4) vasculitis or malignancy at the time of diagnosis.
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Table 2 ICEP patient characteristics at diagnosis
Patient Clinical presentation Biology
Sex Age at
diagnosis
(years)
Atopic
history
Delay to
diagnosis
(days)
Respiratory
symptoms
Respiratory
exam
General
symptoms
Initial blood
Eo count/mm3
Maximal blood
Eo count/mm3
Total
IgE kU/L
Lymphocyte phenotype
1 F 15.5 No 60 ED, RD, DC, T DBS yes 1510 4600 799 normal
2 F 13.9 No 60 ED, RD, DC W, DBS yes 4601 4600 165 normal
3 F 6.8 Yes 120 ED, PC normal no 1100 1100 >5000 normal
4 M 5 Yes 90 DC W no 33,580 48,920 150 2,2% CD3+
CD4- CD8-
with TCR αβ
5 F 11.2 Yes 37 ED, RD, DC, CP H, P yes 80 1300 1040 nd
Patient Biology Imagery Spirometry
T-cell
clonality
ANA BALF
cellularity
(cell/mm3)
BALF
Eo %
BALF
lymphocytes %
BALF
neutrophils %
BALF
macrophages %
Histology CT scan
1 No 1/1280 160,000 28 17 2 53 nd AO, GGO, N,
IST, Ad, B, PE
R, O, D
2 No _ 390,000 44 6 4 46 nd AO, GGO, B,
BV, Ad
R, O, D
3 No 1/100 241,000 21 20 5 52 Positive dGGO, RN R
4 nd _ 450,000 20 5 2 73 nd pGGO, N, Ad R
5 Positive
(TCR γ gene)
nd 112,000 14 16 43 27 nd dGGO, RN,
Ad, PM
nd
Footnote: F: female, M: male, nd: not determined, ED: exertional dyspnea, RD: rest dyspnea, DC: dry cough, T: chest tightness, PC: productive cough, CP: chest pain, DBS: decreased breath sound, W: wheezing,
H: hypoxemia ,P: polypnea, Eo: eosinophils, ANA: antinuclear antibodies, BALF: broncho-alveolar lavage fluid, AO: alveolar opacities, GGO: ground-glass opacities, N: nodules, IST: interlobular septal thickening,
Ad: adenopathy, B: bronchiectasis, PE: pleural effusions, BV: peri-broncho-vascular thickening, RN: reticulonodular syndrome, N, nodules, PM: pneumomediastinum, d: diffuse, p: patchy, , D: diffusion impairment,
R: restriction, O: obstruction, in bold: diagnostic criteria.
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Histological data
Case 3 underwent transbronchial lung biopsies at diagnosis.
Biopsies showed eosinophilic alveolo-interstitial infiltrates
with alveolar septal thickening, eosinophils within the septa
and alveoli filled with eosinophils and macrophages.
Pulmonary function tests
Dynamic lung volume measurement was performed in
four patients at admission. The two oldest patients had a
combined ventilatory defect. The youngest had a decreased
functional respiratory capacity indicating a possible re-
strictive pattern. The carbon monoxide diffusing capacity
was measured in three patients and was abnormal for two
of them.
Treatment and evolution
All except one patient (case 4) received oral corticoste-
roids (Table 3). One patient (case 5) received, in addition
to oral steroids, nine courses of high-dose-regimen intra-
venous corticosteroids (10 mg/kg/day methylprednisolone
Figure 1 HRCT scan in “dramatic improvement subset” ICEP patients. (a) At diagnosis: in case 1, bilateral and peripheral, dense and fluffy
alveolar opacities associated with ground-glass opacities predominantly in the right superior lobe; in case 2, peripheral, alveolar, dense and fluffy
opacities with areas of ground-glass opacities predominantly in the right and also in the left apex; in case 4, patchy ground-glass opacities and
nodules. (b) Last HRCT scan showing complete normalization.
Figure 2 HRCT scan in “persistent diffuse interstitial subset” ICEP patients. (a) At diagnosis: in cases 3 and 5, diffuse ground glass opacities,
reticulonodular syndrome. (b) Last HRCT scan showing diffuse ground-glass opacities with development of thin-walled cysts in cases 3 and 5.
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for 3 days per month). The mean initial dose of oral corti-
costeroids (prednisolone or prednisone) was 1.5 mg/kg/day
(1-2 mg/kg/day). The duration of treatment was highly
variable, with a median of 4 [3.5-6] months. Case 4 was
treated with “low” doses of cyclosporine (5 mg/kg/day) and
was still on maintenance therapy with this treatment after
39 months of follow-up.
All patients presented a rapid clinical improvement,
occuring within the first two weeks of treatment for 4
patients (cases 1, 2, 3, 4) and within the first month for
the fifth (case 5.). Chest X-rays and HRCT scan normal-
ized within one month for three patients and showed
persistent interstitial opacities after the first month for
two (cases 3 and 5) (Figures 1b and 2b).
The median length of follow-up was 5 years 2 months
(range 1 year 5 months – 8 years 2 months). Cases 3 and 5
with persistent interstitial opacities relapsed clinically and
biologically after weaning off initial corticosteroid treat-
ment. These two children had a second regimen of oral
corticosteroids and case 3 is still on maintenance oral cor-
ticosteroid therapy. The last spirometric follow-up showed
a fixed restrictive and peripheral obstructive pattern in
case 3 and was normal for case 5. The most recent HRCT
scan showed thin-walled cyst development two and five
years, respectively, post-episode (Figure 2b).
IAEP
Epidemiology
Three patients were identified (Table 4). There were two
boys and one girl (sex ratio: 2). The median age at diagno-
sis was 14.08 [13.75-15] years. Two patients were current
smokers and all had been exposed to environmental to-
bacco smoke at home for several years. Case 1 reported
smoking cannabis for the first time 3 months ago and on
a second occasion just a few hours before the onset of his
respiratory symptoms. Case 3 reported an acute exposure
to tear gas and a paint stripper containing a solvent mix-
ture of DMSO and lactic acid.
Clinical and biological presentation
The delay between the onset of symptoms and diagnosis
was, respectively, 4, 6 and 21 days. All patients experi-
enced exertional and, rapidly, rest dyspnea. A dry cough
was present in only two patients. General symptoms ap-
peared secondarily in < 48 hours or simultaneously with
elevated fever.
Radiological data
Chest X-rays showed bilateral dense infiltrates and ground-
glass opacities in the three patients. One of the patients de-
veloped bilateral pleural effusion. A CT scan was performed
for two patients and showed typical aspects of the adult
form.
Bronchoalveolar lavage (BAL)
The median BAL cellularity was 350,000 [210,000-
775,000] /mm3. BAL eosinophilia was present in all
cases, with a median of 38 [32-58] %.
Treatment and evolution
All patients initially required ventilatory support with
noninvasive ventilation for a few hours (2/3), invasive
ventilation (3/3) with a median of 5 [3.5-7] days, and
4 days of extracorporeal membrane oxygenation (ECMO)
for case 1 (Table 5). High-dose intravenous corticosteroids
were initiated (4, 6 and 10 mg/kg/day methylprednisolone,
respectively) with a progressive decrease and shift towards
the oral route for a total length of 90, 48 and 42 days, re-
spectively. This treatment resulted in a dramatic clinical
improvement with rapid weaning of ventilator support.
Table 3 ICEP patient treatment and evolution
Patient Treatment Evolution
Initial
treatment
Duration
(months)
Response Total
length of
follow-up
(years)
Relapse
(number)
Delay after the
end of the
initial regimen
(years)
Maintenance
oral CS
Clinical
evolution
Last CT scan Last
spirometry
1 oral CS §
1 mg/kg/day
4 Total 1.5 0 _ _ _ m9: normal
(1 nodule)
D
2 oral CS §
2 mg/kg/day
2 Total 5.9 0 _ _ asthma m1: mild
bronchiectasis
pO
3 oral CS *
1 mg/kg/day
4 Partial 8.1 2 0.8 0.07 mg/kg/day asthma y7: interstitial
opacities and cysts
R, pO
4 cyclosporine
5 mg/kg/day
39 Total 3.2 0 _ _ asthma y3: normal mild R
(obesity)
5 9 IV pulse +
oral CS §
2 mg/kg/day
12 Partial 7.2 1 6.1 _ asthma y6: interstitial
opacities and cysts
normal
Footnote: § prednisolone, * prednisone, IV: intravenous methylprednisolone, CS: corticosteroid therapy, D: diffusion impairment, R: restriction, pO:
peripheral obstruction ,m: month, y: year.
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Table 4 IAEP patient characteristics at diagnosis
Patient Clinical presentation Biology
Sex Age at
diagnosis
(years)
Delay to
diagnosis
(days)
Atopic
history
Active
smoking
Passive
smoking
Chronic
exposure
Acute
exposure
Initial blood
Eo count/mm3
Maximal blood
Eo count/mm3
Total
IgE kU/L
1 M 15.9 4 Yes Yes Yes Dog, budgerigars Cannabis 200 3100 nd
2 F 13.4 6 Yes Yes Yes Dog, cat No nd 680 54
3 M 14.1 21 No No Yes No Teargas, vironet 7800 8500 20.2
Patient Biology Imagery
Lymphocyte
phenotype
ANA BALF cellularity
(cells/mm3)
BALF Eo % BALF lympho
cytes %
BALF neutrophils % BALF macro
phages %
Chest X-rays CT scan
1 nd _ 350,000 38 16 18 28 AO, IO AO, GGO, IST,
BVT, PE
2 Normal _ 70,000 26 11 33 30 AO,IO,PE AO, PE
3 nd _ 1,200,000 78 7 7 8 AO, IO nd
Footnote: F: female, M: male, nd: not determined, Eo: eosinophils, ANA: antinuclear antibodies, BALF: broncho-alveolar lavage fluid, AO: alveolar opacities, IO: interstitial opacities, PE: pleural effusion, GGO: ground-
glass opacities, IST: interlobular septal thickening, BVT: peribronchiovascular thickening, in bold: diagnostic criteria.
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Chest X-ray controls at 6 and 11 days were normal. The
CT scan was considered normal at one month for case 2
and at 8 months for case 3. Spirometry performed at two
months was normal for cases 1 and 3, but showed a de-
creased carbon monoxide transfer factor and transfer co-
efficient in case 2. None of the patients relapsed.
Discussion
We present the first series of pediatric ICEP and IAEP
diagnosed in a 5-year time frame in the same network of
French Rare Lung Diseases.
ICEP
Described by Carrington et al. [5], ICEP is a rare disease
accounting for < 3% of interstitial diseases, but it is the
major cause of eosinophilic lung disease in countries
with a low prevalence of parasitic infections. It predomi-
nates in females (sex ratio 0.5) with a mean age at diag-
nosis of 45 years, and less than 6% of patients are less
than 20 years old [3]. More than 50% of cases have a
prior history of atopy and asthma [6]. Patients are usually
nonsmokers. ICEP has a progressive onset with develop-
ment of respiratory (mild dyspnea, cough) and systemic (fa-
tigue, malaise, fever, anorexia, night sweats and weight loss)
symptoms over several weeks. The imaging features are
rather characteristic with, in almost all cases, bilateral per-
ipheral alveolar infiltrates with ill-defined margins on the
chest radiograph and coexisting peripheral ground-glass on
CT scan [4]. The blood eosinophil count is elevated in 90%
of cases. BAL eosinophilia is now a major diagnostic pro-
cedure in ICEP: it is always present, commonly at around
40% in adults. ICEP responds dramatically, clinically, bio-
logically and radiologically, to oral corticosteroids in adults
and a short regimen of 6 weeks is now used. Relapses are
frequent (> 50%) and require a longer regimen with low-
dose corticosteroid therapy [7].
ICEP is extremely rare in children. To date, only ten
pediatric observations have been reported in the litera-
ture [8-14], apart from those published by our center
[15-17], with no follow-up studies or series (Table 6).
Diagnosis in children has relied on adult criteria [3], as
used in this study. Lung biopsy, no longer required for
diagnosis, shows eosinophilic infiltration of the lung
structures.
Our study has collected comprehensive data for all the
pediatric cases diagnosed and allows some comparisons to
be made with the typical adult form [7], even though the
number of subjects is limited. Only two patients out of five
had alveolar opacities and three had an interstitial aspect
with ground-glass opacities and micronodular syndrome
and for two of them a persistence of initial elements, with
the late appearance of thin-walled cysts for both. We can
thus distinguish two main subsets of patients.
The first subset (cases 1, 2 and 4) had a dramatic clin-
ical, radiological and biological improvement after the
first line of treatment, with no relapse to date. Cases 1
and 2 had a similar form to adults, and recovered fully after
initial oral corticosteroid treatment. Case 4 had a 2.2% ab-
normal T-lymphocyte (TL) clone and a respiratory-only
presentation with “patchy-only-interstitial” HRCT scan.
The distinction between lymphoid-variant hypereosinophi-
lic syndrome (L-HES) [18] and ICEP was questionable for
this case. Indeed lung involvement in HES consists mainly
of patchy ground-glass opacities as presented by our pa-
tient [19]. However, we considered that case 4 had ICEP,
considering the respiratory-only setting (single-organ dis-
ease) without any other organ involvement at diagnosis
and during follow-up (clinical follow-up and cardiac ultra-
sound performed at 1 month, 6 months and then yearly)
Table 5 IAEP patient treatment and evolution
Patient Treatment Evolution
Ventilatory support Corticosteroid treatment Total length
of follow up
Asthma Last
spirometry
Last
CT scan
NIV MV ECMO paO2/
FiO2
IVCS OCS
start dose
Total
length
Response
1 _ 5 days _ 77 4
mg/kg/day
prednisolone
2 mg/kg/day
3 months Total 3 years Yes Normal nd
10 months1 week
7 days
2 few hours 9 days 4 days 45 6-4
mg/kg/day
prednisone
2 mg/kg/day
48 days Total 9 months No D Normal
9 days
3 24 h before,
48 h after MV
2 days _ 50 10
mg/kg/day
prednisolone
1 mg/kg/day
6 weeks Total 8 months No Normal
(DLCO
not done)
Normal
3 days
Footnote: NIV: noninvasive ventilation, MV: mechanical ventilation, ECMO: ExtraCorporeal Membrane Oxygenation, IVCS: intravenous corticosteroid therapy, OCS:
oral corticosteroid therapy, D: diffusion impairment.
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[18] and the low level of the abnormal TL clone in com-
parison with levels reported in L-HES [20] – this clone
having been described at low levels in the general popu-
lation [21]. Moreover, Cottin et al. recently reported T-cell
abnormalities in eosinophilic lung disease, showing that
the pathophysiologic boundary with HES may be very thin
(1/9 adult patients with ICEP had T-cell receptor gamma
rearrangements and 1/57 adults with eosinophilic lung
disease had an aberrant T-cell population immunopheno-
type) [22].
The other subset (cases 3 and 5) had a persistent inter-
stitial form with the appearance of thin-walled cysts for
both after more than five years of stability of the initial
lesions for case 5 and two years of follow-up for case 3.
They, moreover, had very limited general symptoms and
less peripheral blood hypereosinophilia as well as lower
BAL eosinophilia compared to the adults. One patient
had, at diagnosis, a biopsy showing an initially typical
histological aspect of ICEP. The other patient had a T-
cell clonality, as recently described in ICEP [22]. Their
clinical and radiological follow-up might, nevertheless,
suggest revisiting the final diagnosis. Indeed, mild BALF
eosinophilia has been described in adult idiopathic pul-
monary fibrosis (IPF), in up to 50% of patients with des-
quamative interstitial pneumonia (DIP), in cryptogenic
organizing pneumonias and nonspecific interstitial pneu-
monitis [23-27]. Peripheral blood eosinophilia is rarely
found in UIP and DIP (around 10% of cases) [27]. ICEP
can evolve, moreover, spontaneously into lung fibrosis
with a DIP-like reaction [28]. All of these data indicate
that there is still a place for lung biopsy in the diagnosis
of ICEP when the initial setting and evolution are not
usual. The modality of these biopsies also needs to be
clarified, as case 3, with an unusual evolution, was initially
described as having a standard histopahologic finding of
ICEP on transbronchial biopsies. In cases not responding
to initial oral corticosteroid treatment, diagnostic biopsies
should be performed after a period of weaning off treat-
ment, to contribute to the differential diagnosis between
ICEP and idiopathic interstitial pneumonia. However, the
optimal length and the feasibility of this weaning period
need to be established.
The frequency of unusual forms in this first pediatric
national series suggests the specification of a more strict
pediatric definition, including the definition of the require-
ment for biopsy. The treatment regimens of these patients
should be modified and the use of corticosteroid-sparing
agents in the context of an eosinophil-triggered disease
evaluated (omalizumab, mepolizumab) [29]. Low-dose cy-
closporine, used by other teams in lymphoid-variant HES
and idiopathic HES [30], should be further evaluated in the
context of eosinophilic pneumonias [31], and especially in
persistent forms of ICEP.
Regarding hypereosinophilic asthma, the boundary
[32] can be very difficult to specify in young children,
and two patients who were excluded from our cohort
were finally classified as asthmatic. Hypereosinophilic
asthma can be observed in pediatric patients with > 25%
eosinophils in BALF. Asthma attacks are induced by
viral infections in 80% of cases [33] and alveolar opaci-
ties and atelectasis are frequent. Limits can be difficult
to establish initially as more than 50% of ICEP patients
have previously been diagnosed as asthmatic [7]. Only
the clinical evolution of the patient can help the evalu-
ation of the clinician.
In order to consider these pediatric specificities, the
definition of ICEP could be clarified in children as:
i) diffuse pulmonary alveolar consolidation with air
bronchogram and/or ground-glass opacities, especially
with peripheral predominance;
Table 6 Data from the literature on pediatric ICEP
Year First Author Journal Sex Age at
diagnosis
(years)
Asthma
history
Fever Blood Eo
count/mm3
BALF Histology Total length
treatment
(months)
Relapse Chest
X-rays
CT scan
1975 Rao M Chest M 1 No Yes Elevated No Yes 12 No AO, Ad nd
1992 Naughton M Chest F 15 Yes No 3200 nd No 9 Multiple AO nd
1993 O’ Sullivan BP J Pediatr M 14.9 Yes Yes 3350 No Yes nd nd AO AO, BBO
2000 Oermann C J Pediatr F 16.1 No No 4030 No Yes nd No AO, IO nd
2003 Wubbel C Chest F 6-10 nd nd nd nd nd nd nd nd nd
2003 Wubbel C Chest F 6-10 nd nd nd nd nd nd nd nd nd
2003 Wubbel C Chest M 11-16 Yes Yes 9504 Yes Yes nd nd nd AO
2003 Wubbel C Chest M 11-16 nd nd nd nd nd nd nd nd nd
2005 Tanir G TuberkToraks M 4 Yes nd 2626 Yes Yes nd nd nd AO, GGO
2010 Cakir E Pediatr
Pulmonol
F 7 Yes No 2205 Yes No 6 No nd AO, GGO
Footnote: F: female, M: male, nd: not determined, Eo: eosinophils, BALF: broncho-alveolar lavage fluid, AO: alveolar opacity, IO: interstitial opacities, Ad: adenopathy,
BBO: basal band of opacities, GGO: ground-glass opacities.
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ii) BALF eosinophilia > 20% or peripheral blood eosino-
philia > 1×109 cells/L;
iii) respiratory symptoms present for more than 4 weeks;
iv) absence of other known causes of eosinophilic lung
disease;
v) consistent open lung biopsy for cases without initial
dramatic clinical AND radiological improvement on first-
line treatment.
Two items of adult classification concerning imaging
and the exclusion of differential diagnoses were not chan-
ged. Clinical and biological aspects were adapted in order
to be fulfilled by most of the pediatric cases. As discussed
previously, the requirement for open lung biopsy has been
specified in cases of resistance to first-line treatment.
A new classification algorithm for eosinophilic pneu-
monia in children is also proposed (Figure 3), including
two main differential diagnoses to ICEP: hypereosinophilic
asthma and idiopathic interstitial pneumonia. The overall
impression is that idiopathic chronic eosinophilic pneu-
monia is part of the clinical spectrum of a wider group of
lung diseases, with some potential overlap between them,
making a clear distinction sometimes difficult. Molecular
analysis should likely help in the clarification of this aspect
and better circumvent underlying biological processes.
IAEP
We describe three cases of IAEP in adolescents. Specific
descriptions of pediatric IAEP are rare [34-36], but such
patients have also been included in series mixed with
adults [37]. To date, no specific pediatric series have been
described but pediatric cases are often adolescents. Acute
exposure to irritants was found in our series (smoke,
cannabis, paint stripper and tear gas), as in adults. The
severity of respiratory distress requiring ECMO 24 hours
after hospitalization and 48 hours after the beginning of
symptoms has never been described in adults. This does
not correspond to a delay in medical care but rather to
the rapid development of an aggressive pathology. Other
clinical, biological and radiological aspects of these pa-
tients seem similar to those in adults. The length of ster-
oid treatment was highly variable, as in adults, and should
be reduced to two weeks [38]. Treatment resulted, as in
adults, in a dramatic clinical improvement, with rapid
weaning of ventilator support. None of the patients re-
lapsed. CT scan control was normal and initial spirometric
follow-up showed only minor alterations.
Conclusion
ICEP in children, even respecting the definition estab-
lished by adults, seems to be polymorphous. We propose
here a specific pediatric definition of ICEP and we argue
for an open lung biopsy proof of the disease in persistent
interstitial forms. As in adults, oral steroids seem to be
an efficient treatment in children, and the duration could
probably be shortened in classical forms. New therapeutic
options in ICEP (mepolizumab, omalizumab,…) could be
interesting in order to spare oral corticosteroids. IAEP
seems to be similar in its initial presentation to adult
forms in our series but its short-term course may be more
severe, nevertheless with a good prognosis. This study
represents the largest pediatric cohort ever described in
the literature, but is still based on a small number of pa-
tients. These pediatric orphan diseases should be regis-
tered internationally in order to improve our knowledge,
especially in chronic forms.
Figure 3 Classification algorithm in pediatric eosinophilic pneumonias.
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